Birdwatch Note
2023-02-05 16:42:19 UTC - NOT_MISLEADING
FDA's own definition confirms mRNA is a gene therapy: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy Regulatory filings from Moderna to the SEC also confirm mRNA is gene therapy according to the FDA: https://www.sec.gov/Archives/edgar/data/1682852/000168285220000017/mrna-20200630.htm "Currently, mRNA is considered a gene therapy product by the FDA"
Written by C577259366B49D2C4213F5935B3CCD8B444D7A18AA9D098CECC73436143CC310
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1621728404142686208
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1622274429941170176
- noteId - 1622274429941170176
- participantId - C577259366B49D2C4213F5935B3CCD8B444D7A18AA9D098CECC73436143CC310
- noteAuthorParticipantId -
- createdAtMillis - 1675615339155
- tweetId - 1621728404142686208
- classification - NOT_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 1
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- FDA's own definition confirms mRNA is a gene therapy: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy Regulatory filings from Moderna to the SEC also confirm mRNA is gene therapy according to the FDA: https://www.sec.gov/Archives/edgar/data/1682852/000168285220000017/mrna-20200630.htm "Currently, mRNA is considered a gene therapy product by the FDA"
Note Ratings
rated at | rated by | |
2023-02-05 15:19:53 -0600 | 0097C32B4C739467556C3096A0542B2301B756CE6A4C761A1A926FEC754C4F76 | Rating Details |
2023-02-05 10:55:47 -0600 | 0A2556A9597492279062F08E5C027BEDEA120E6893F9355FCCBC532CA1AF4705 | Rating Details |
2023-02-05 11:15:32 -0600 | 0A5B082A68C6F3150A476B9F59E72F0707D89B0432BF7DF9388190A7045E7C9D | Rating Details |
2023-02-05 12:47:13 -0600 | 0DAB2E6C1C2CD5A9769CABB1F15FEEDB20400FA819197225F0BD4B49540A6032 | Rating Details |
2023-02-05 14:43:34 -0600 | 17FC9A86B53584287A4CCB0473F7FC301803266886168B8457FC8DD53F5CCB1A | Rating Details |
2023-02-05 12:58:36 -0600 | 3F1165663D5EB75F614A51CED0953897D46E7F8D6E2AA4E5E845D88F266CE5BF | Rating Details |
2023-02-05 13:22:45 -0600 | 479F823F1C14B7E79D4DDECC452FA3B619E14E376DEB831A7DFE7EBACD79C2E2 | Rating Details |
2023-02-05 14:16:59 -0600 | 47AD3BD4ED0E64C9EA74DB3A322FA6AA5E5F8D84E57A6E405CC624F53C571EC8 | Rating Details |
2023-02-05 13:02:05 -0600 | 4CFF19BD69F823E18A5AFBF5CD7648436BD1D8B0C02EBB4B6789AA19064063E0 | Rating Details |
2023-02-05 13:38:31 -0600 | 50E7187C9CC47AE62C79178490824ED05E11DB89C8EB21C62A1D2EA996CF44AF | Rating Details |
2023-02-05 10:58:48 -0600 | 5829E3F8AEA2104FD6A130671D63B55ED9377F8D982628CAAE1A585C71B98321 | Rating Details |
2023-02-07 03:38:46 -0600 | 6337731A457BF30A108A2C4F898B79CCECA99F1E613082DD40A7A258A3E88BBA | Rating Details |
2023-02-05 12:32:44 -0600 | 637861D96F0B29C657D34ADCEC55F676B9D2F33DB91B94D711C52B1C18CA2AF8 | Rating Details |
2023-02-05 14:46:05 -0600 | 64CC132DAA84B27739164B4933D998F54F1D0AD3527B3BAF0478BA457EFBCF7B | Rating Details |
2023-02-05 20:17:45 -0600 | 6BC6AD03F96780F5C95E2F5DF48BE87DC02C60959DB7792DBE8BE8CFD018B3C3 | Rating Details |
2023-02-05 13:24:56 -0600 | 727B0035D1213E725BB76F326E71E547490592F1E75BE08C016513F4C121D1CC | Rating Details |
2023-02-05 12:13:38 -0600 | 74C1641B0692174A46A4DB704290BCBF96132765CE28D582BD3C7E5BD38C296D | Rating Details |
2023-02-05 11:37:27 -0600 | 7549412981BC0CD32F65402AF2966DD0A35707671DDCCEF312A1FB66772B131D | Rating Details |
2023-02-05 13:00:53 -0600 | 7DAF7E766C91C4681BD9E35A65ED1244CD021FD7E551BF6AB85D6DF31D7EAC10 | Rating Details |
2023-02-05 12:23:20 -0600 | 803CEE394E0F3E70D4176A8A2D86F197E68B4CD82367AF3F816B5669B0545937 | Rating Details |
2023-02-12 16:25:01 -0600 | 809A7EC92C85118887141E104B706D53AF6DF0FFEB4F82C5B7F5143BB81B9357 | Rating Details |
2023-02-05 15:51:07 -0600 | 8CFD3C4B87DEFD2E808B932B71FC15C87467D38439124F333ED58AFD23C6BB6C | Rating Details |
2023-02-05 17:27:46 -0600 | 8EC052F7942E203BF07D1FCECEF1DBDE3F52F4FD18D1B6A7B0B0A99D155C64BB | Rating Details |
2023-02-05 12:13:52 -0600 | 8EEB74836816E3149B6EA4E6F39D736189B150426AF4DDD0CFCC0BFF0B081BBF | Rating Details |
2023-02-05 11:21:50 -0600 | 91ED1050C69AB445CFA549CAAF55F48AAC56D267EAADDF024A57D453A99233C4 | Rating Details |
2023-02-05 14:42:56 -0600 | 983039B3AE04269183DE6E9D3C95574FB4EF5B7B12064E5C2B3929509F3ABF29 | Rating Details |
2023-02-05 21:11:22 -0600 | 98A87070D6FF6B5AC1D0EF707CE79E9C0297670157D696A269B3C8CDEF59375E | Rating Details |
2023-02-05 12:08:39 -0600 | 998F86FC603EC49F17CC21E1C2FE0911E798339AD580C6E41A76EF1A5D30E56A | Rating Details |
2023-02-05 11:51:31 -0600 | A1A3CEBE1775A06C024D0C3849A7A3C1B802A20DC198F0974F4084B92DCDBDE8 | Rating Details |
2023-02-05 10:58:01 -0600 | A30E23B01F927C4387616E33DE422C96B4F9A9B45B8ACA619267391F3D77B5A8 | Rating Details |
2023-02-05 12:12:08 -0600 | AB465CA1F3AA15CE72433F9AE21516C2DEF53A5D11B2F2AB229037579530AFD5 | Rating Details |
2023-02-18 10:32:08 -0600 | AC39CC2C21BF5800072D53B804A0C9FDA8E60B99D864D7F5EDBF2DBE6D4C514D | Rating Details |
2023-02-05 14:48:09 -0600 | B490010CDC0FF1CDF0A602D3930EC338876F1CFA94BAFDE0450EB744378BEF7A | Rating Details |
2023-02-05 10:51:58 -0600 | B4B6F4C9869B224028F9E78FD0074284080E4EA1D3DF6BD018A1272EB8866FE5 | Rating Details |
2023-02-05 13:53:04 -0600 | C47F0E08D5CE6DFECD20CAFA068C81BF35BFEA8F9DBF3DFA57CF3F2F8B8D1994 | Rating Details |
2023-02-05 13:46:44 -0600 | C5E0C9C555734997902F2CC672D3C6F98AD9A5C92580B6A5A72B3B3D6B1B9696 | Rating Details |
2023-02-05 13:44:08 -0600 | C755682B8E9A972BB455C8E990298A43633BA5C83B4750B33D2F2A03D1656C05 | Rating Details |
2023-02-05 12:08:32 -0600 | D02A00B1DFC1CFFE06413663F4109A35AE32B07B022EBD453E01E9ED0141CDC9 | Rating Details |
2023-02-05 13:10:19 -0600 | D624A12EEF282542650249A8D1405F3C15B34959699367D694CA3BA75FBC08D3 | Rating Details |
2023-02-16 18:45:57 -0600 | DED5B41533E09EEE31FEC38195691C41C698EC5E17DBB8480F98BDE36077014A | Rating Details |
2023-02-05 13:38:16 -0600 | E343F092F0B44A6E8DEC7F3A16DFE90A5DA9F420CB1B9EDE2292D0B45E00C827 | Rating Details |
2023-02-05 12:06:24 -0600 | E72B68963607595460B2C1CC0B37FB6351F4EBF6CB64154317884F89470ABFD0 | Rating Details |
2023-02-10 14:09:40 -0600 | E7968A03811F71A1FD36DCCC0FD364C0FCCA9BF9B1740AEA4D2E914D1A3F7384 | Rating Details |
2023-02-05 13:18:34 -0600 | F810B9A117A15B206340CC72B29D65263DC4B812622393BFCBE22D0EE5EE3DFF | Rating Details |
2023-04-09 17:17:21 -0500 | Rating Details | |
2023-02-05 11:07:53 -0600 | Rating Details | |
2023-02-05 12:13:38 -0600 | Rating Details | |
2023-04-09 17:17:21 -0500 | Rating Details | |
2023-02-05 11:21:50 -0600 | Rating Details | |
2023-02-05 12:13:52 -0600 | Rating Details | |
2023-02-05 13:22:45 -0600 | Rating Details | |
2023-02-05 17:27:46 -0600 | Rating Details | |
2023-02-05 10:55:47 -0600 | Rating Details | |
2023-02-05 20:17:45 -0600 | Rating Details | |
2023-02-05 12:12:08 -0600 | Rating Details | |
2023-02-05 12:58:36 -0600 | Rating Details | |
2023-02-05 12:08:39 -0600 | Rating Details | |
2023-02-05 13:38:16 -0600 | Rating Details | |
2023-02-05 12:47:13 -0600 | Rating Details | |
2023-02-05 12:08:32 -0600 | Rating Details | |
2023-02-05 21:11:22 -0600 | Rating Details | |
2023-02-05 15:51:07 -0600 | Rating Details | |
2023-02-10 14:09:40 -0600 | Rating Details | |
2023-02-16 18:45:57 -0600 | Rating Details | |
2023-02-05 10:51:58 -0600 | Rating Details | |
2023-02-05 13:24:56 -0600 | Rating Details | |
2023-02-05 13:38:31 -0600 | Rating Details | |
2023-02-05 12:06:24 -0600 | Rating Details | |
2023-02-05 14:42:56 -0600 | Rating Details | |
2023-02-05 12:23:20 -0600 | Rating Details | |
2023-02-05 13:00:53 -0600 | Rating Details | |
2023-02-05 12:32:44 -0600 | Rating Details | |
2023-02-05 11:37:27 -0600 | Rating Details | |
2023-02-05 11:15:32 -0600 | Rating Details | |
2023-02-05 10:58:01 -0600 | Rating Details | |
2023-02-12 16:25:01 -0600 | Rating Details | |
2023-02-05 14:43:34 -0600 | Rating Details | |
2023-02-05 13:18:34 -0600 | Rating Details | |
2023-02-05 13:46:44 -0600 | Rating Details | |
2023-02-05 11:51:31 -0600 | Rating Details | |
2023-02-05 11:07:53 -0600 | Rating Details | |
2023-02-05 15:19:53 -0600 | Rating Details | |
2023-02-05 14:48:09 -0600 | Rating Details | |
2023-02-05 13:53:04 -0600 | Rating Details | |
2023-02-05 14:16:59 -0600 | Rating Details | |
2023-02-07 03:38:46 -0600 | Rating Details | |
2023-02-05 14:46:05 -0600 | Rating Details | |
2023-02-05 13:02:05 -0600 | Rating Details | |
2023-02-05 13:10:19 -0600 | Rating Details | |
2023-02-05 10:58:48 -0600 | Rating Details | |
2023-02-05 13:44:08 -0600 | Rating Details |